课题基金 / 基金详情

Pharmacological Management of Pain in Alzheimer's Disease and Related Dementia

Pharmacological Management of Pain in Alzheimer's Disease and Related Dementia
阿尔茨海默病和相关痴呆症疼痛的药理学治疗
批准号:
10187473
负责人:
Yu-Jung Wei
金额:
$12.44万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-01 至 2022-05-31

项目摘要

项目成果

Yu-Jung Wei的其他基金

相似基金

相关文献

中文摘要
翻译
我的职业目标是成为一名独立的老年药物流行病学家
英文摘要
Summary: My career goal is to become an independent geriatric pharmacoepidemiologist with expertise in pharmacotherapy quality measurement and outcomes evaluation in the fields of pain and aging. The clinical focus of my research has centered on the management of multi-morbidity in older adults and particularly, the interplay of mental and physical disease and its treatment. One example of combination of health problems is elderly patients who live with Alzheimer's disease and related dementia (ADRD) and also suffer from chronic pain. To date, data on quality of pain medication prescribing and the sequelae of poor pain control in patients with ADRD are scarce. Studies investigating these associations are limited by small sample size, and none has attempted to establish the effect of adequate pain control on preventing mental health (MH) disorders. The goal of my K01 proposed research is to provide preliminary data that improve our understanding of current pain medication prescribing and potential discrepancies between practices and pain guidelines, and to formulate hypotheses for future research regarding the role of pain control in reducing MH problems in ADRD. We propose a longitudinal design using 4 years (2011-2014) of Medicare 5% sample whose billing records are linked to nursing home resident assessment data (Minimum Data Set, MDS, 3.0). Because it is unclear whether MDS 3.0 can accurately detect patients with pain and MH disorders, we first conduct a feasibility study of validating MDS-based pain, depression, and behavioral symptoms against medical records at two nursing homes (Aim 1). With the nationally representative Medicare-MDS data, we explore the quality of pharmacological pain management and its determinants among ADRD and non-ADRD residents with non- cancer pain (Aim 2). The quality will be examined based on five common clinical standards--pain medication selection, pain medication scheduling, pharmacological prevention of drug adverse event, contraindicated medication use, and overall pain control. We then explore the extent to which pain control is associated with a decreased risk for select MH disorders, including depression, behavioral symptoms, anxiety, and sleep disorders in ADRD (Aim 3). This project is well tailored for me to apply the knowledge and skills that will be obtained from training activities with my Primary Mentor, Dr. Almut Winterstein (pharmacoepidemioloy, quality measurement and outcome assessment) and Co-Mentors: Drs. Roger Fillingim (pain), Marco Pahor (aging), Babette Brumback (advanced methods for longitudinal data), and Laurence Solberg (clinical geriatric care and assessment). For further guidance, I enlist the expertise of Dr. Siegfried Schmidt in the field of pain medicine and Dr. Steven DeKosky in ADRD. This K01 award will provide protected time for me to receive training needed to prepare an R01 grant application to examine pain medication practices and their impact on health outcomes in ADRD. The results from this line of research are expected to lead to better pharmacological pain management and improved pain and health outcomes in older adults with cognitive impairments.
期刊论文(5)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.jamda.2021.05.010
发表时间: 2021-10
期刊: Journal of the American Medical Directors Association
影响因子: 7.6
作者: [Jenny Wei YJ, Chen C, Fillingim RB, DeKosky ST, Schmidt S, Pahor M, Solberg L, Winterstein AG]
通讯作者: Winterstein AG
DOI: 10.1371/journal.pmed.1003921
发表时间: 2022-03
期刊: PLoS medicine
影响因子: 15.8
作者: [Chen C, Winterstein AG, Lo-Ciganic WH, Tighe PJ, Wei YJ]
通讯作者: Wei YJ
DOI: 10.1016/j.amepre.2021.07.020
发表时间: 2022-03
期刊: American journal of preventive medicine
影响因子: 5.5
作者: [Wei YJ, Chen C, Winterstein AG]
通讯作者: Winterstein AG
Clinical utility and perils of prescription drug monitoring program-based alert systems.
基于处方药监测程序的警报系统的临床效用和风险。
DOI: 10.1097/j.pain.0000000000001157
发表时间: 2018
期刊: Pain
影响因子: 7.4
作者: [Hincapie-Castillo,JuanM, Wei,Yu-Jung, Winterstein,AlmutG]
通讯作者: Winterstein,AlmutG
Pain, Multimorbidity, Opioid-Drug Interactions and Risk for Opioid Use Disorder or Overdose in Older Adults
  • 批准号:
    10659436
  • 项目类别:
  • 资助金额:
    $40.0万
  • 财政年份:
    2023
  • 负责人:
    Yu-Jung Wei
  • 依托单位:
Opioid Prescribing Practices and Health Outcomes among Patients with Alzheimer's Disease and Related Dementia
  • 批准号:
    10693853
  • 项目类别:
  • 资助金额:
    $53.86万
  • 财政年份:
    2022
  • 负责人:
    Yu-Jung Wei
  • 依托单位:
Opioid Prescribing Practices and Health Outcomes among Patients with Alzheimer's Disease and Related Dementia
  • 批准号:
    10444395
  • 项目类别:
  • 资助金额:
    $54.08万
  • 财政年份:
    2022
  • 负责人:
    Yu-Jung Wei
  • 依托单位:
Prescription Opioid Use Trajectories and Risk Factors Associated with Opioid-Related Hospitalizations in Older Adults
  • 批准号:
    10004049
  • 项目类别:
  • 资助金额:
    $4.85万
  • 财政年份:
    2019
  • 负责人:
    Yu-Jung Wei
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: